Oakland, California, Feb. 26, 2019 (GLOBE NEWSWIRE) — A new report from Arcview Market Research (“Arcview Group”) and BDS Analytics details the many ways in which the cannabis industry could potentially disrupt the pharmaceutical industry. Entitled “Pharmacies vs. Dispensaries: The Future of Cannabinoids as Medicine,” the report explains that the pharmaceutical industry stands to be changed by the popularization of cannabis in two ways: the emergence of cannabis-derived pharmaceutical drugs, and the possible competition between pharmacies and dispensaries as customers begin to trust cannabis to alleviate health issues.
“A slow pace of change is typical of the pharmaceutical industry, but medical cannabis could change that,” said Troy Dayton, CEO of the Arcview Group. “It was the medical cannabis industry that initially provided CBD-based relief to children with epileptic seizures, and is currently helping thousands of patients who are suffering from a vast array of other conditions. Now, the pharmaceutical industry is slowly emerging from 80 years of prohibition-induced neglect towards the potential of cannabis-plant medicines.”
The report indicates that cannabinoid pharmaceutical sales are unlikely to take off in the near term, as only five cannabinoid-based pharmaceuticals are in third-stage trials, and therefore have a